AZTR Azitra Corporation Total Debt to Capital

Azitra, Inc. (AZTR) maintains a high medical reputation due to its safe proteins designed to combat skin dryness. The company's price evolution reflects a debt load of 0.06, while the business relies on unique patents for bacterial modification, with profits contingent upon test results. Additionally, the firm adheres to environmental regulations by minimizing toxic emissions and optimizing the energy costs of its laboratories.

For Azitra, Inc. (AZTR), which utilizes a full outsourcing development model via CROs and CMOs, the leverage ratio—total debt to equity—is critical for assessing financial stability in the absence of proprietary manufacturing assets. The current value of 0.06 reflects the proportion of borrowed funds within the balance sheet structure, where an increasing ratio signals a rise in debt load relative to the company's equity.